FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165157607> ?p ?o ?g. }

• W3165157607 endingPage "e1003615" @default.
• W3165157607 startingPage "e1003615" @default.
• W3165157607 abstract "While Alzheimer disease (AD) and vascular dementia (VaD) may be accelerated by hypercholesterolemia, the mechanisms underlying this association are unclear. We tested whether dysregulation of cholesterol catabolism, through its conversion to primary bile acids (BAs), was associated with dementia pathogenesis.We used a 3-step study design to examine the role of the primary BAs, cholic acid (CA), and chenodeoxycholic acid (CDCA) as well as their principal biosynthetic precursor, 7α-hydroxycholesterol (7α-OHC), in dementia. In Step 1, we tested whether serum markers of cholesterol catabolism were associated with brain amyloid accumulation, white matter lesions (WMLs), and brain atrophy. In Step 2, we tested whether exposure to bile acid sequestrants (BAS) was associated with risk of dementia. In Step 3, we examined plausible mechanisms underlying these findings by testing whether brain levels of primary BAs and gene expression of their principal receptors are altered in AD. Step 1: We assayed serum concentrations CA, CDCA, and 7α-OHC and used linear regression and mixed effects models to test their associations with brain amyloid accumulation (N = 141), WMLs, and brain atrophy (N = 134) in the Baltimore Longitudinal Study of Aging (BLSA). The BLSA is an ongoing, community-based cohort study that began in 1958. Participants in the BLSA neuroimaging sample were approximately 46% male with a mean age of 76 years; longitudinal analyses included an average of 2.5 follow-up magnetic resonance imaging (MRI) visits. We used the Alzheimer's Disease Neuroimaging Initiative (ADNI) (N = 1,666) to validate longitudinal neuroimaging results in BLSA. ADNI is an ongoing, community-based cohort study that began in 2003. Participants were approximately 55% male with a mean age of 74 years; longitudinal analyses included an average of 5.2 follow-up MRI visits. Lower serum concentrations of 7α-OHC, CA, and CDCA were associated with higher brain amyloid deposition (p = 0.041), faster WML accumulation (p = 0.050), and faster brain atrophy mainly (false discovery rate [FDR] p = <0.001-0.013) in males in BLSA. In ADNI, we found a modest sex-specific effect indicating that lower serum concentrations of CA and CDCA were associated with faster brain atrophy (FDR p = 0.049) in males.Step 2: In the Clinical Practice Research Datalink (CPRD) dataset, covering >4 million registrants from general practice clinics in the United Kingdom, we tested whether patients using BAS (BAS users; 3,208 with ≥2 prescriptions), which reduce circulating BAs and increase cholesterol catabolism, had altered dementia risk compared to those on non-statin lipid-modifying therapies (LMT users; 23,483 with ≥2 prescriptions). Patients in the study (BAS/LMT) were approximately 34%/38% male and with a mean age of 65/68 years; follow-up time was 4.7/5.7 years. We found that BAS use was not significantly associated with risk of all-cause dementia (hazard ratio (HR) = 1.03, 95% confidence interval (CI) = 0.72-1.46, p = 0.88) or its subtypes. We found a significant difference between the risk of VaD in males compared to females (p = 0.040) and a significant dose-response relationship between BAS use and risk of VaD (p-trend = 0.045) in males.Step 3: We assayed brain tissue concentrations of CA and CDCA comparing AD and control (CON) samples in the BLSA autopsy cohort (N = 29). Participants in the BLSA autopsy cohort (AD/CON) were approximately 50%/77% male with a mean age of 87/82 years. We analyzed single-cell RNA sequencing (scRNA-Seq) data to compare brain BA receptor gene expression between AD and CON samples from the Religious Orders Study and Memory and Aging Project (ROSMAP) cohort (N = 46). ROSMAP is an ongoing, community-based cohort study that began in 1994. Participants (AD/CON) were approximately 56%/36% male with a mean age of 85/85 years. In BLSA, we found that CA and CDCA were detectable in postmortem brain tissue samples and were marginally higher in AD samples compared to CON. In ROSMAP, we found sex-specific differences in altered neuronal gene expression of BA receptors in AD. Study limitations include the small sample sizes in the BLSA cohort and likely inaccuracies in the clinical diagnosis of dementia subtypes in primary care settings.We combined targeted metabolomics in serum and amyloid positron emission tomography (PET) and MRI of the brain with pharmacoepidemiologic analysis to implicate dysregulation of cholesterol catabolism in dementia pathogenesis. We observed that lower serum BA concentration mainly in males is associated with neuroimaging markers of dementia, and pharmacological lowering of BA levels may be associated with higher risk of VaD in males. We hypothesize that dysregulation of BA signaling pathways in the brain may represent a plausible biologic mechanism underlying these results. Together, our observations suggest a novel mechanism relating abnormalities in cholesterol catabolism to risk of dementia." @default.
• W3165157607 created "2021-06-07" @default.
• W3165157607 creator A5000122559 @default.
• W3165157607 creator A5003099024 @default.
• W3165157607 creator A5003112344 @default.
• W3165157607 creator A5014075642 @default.
• W3165157607 creator A5024778068 @default.
• W3165157607 creator A5025091889 @default.
• W3165157607 creator A5026497723 @default.
• W3165157607 creator A5028538999 @default.
• W3165157607 creator A5033079155 @default.
• W3165157607 creator A5034999945 @default.
• W3165157607 creator A5037297600 @default.
• W3165157607 creator A5037878316 @default.
• W3165157607 creator A5044201977 @default.
• W3165157607 creator A5045604301 @default.
• W3165157607 creator A5045807277 @default.
• W3165157607 creator A5045907715 @default.
• W3165157607 creator A5047843839 @default.
• W3165157607 creator A5048570234 @default.
• W3165157607 creator A5069442898 @default.
• W3165157607 creator A5070378721 @default.
• W3165157607 creator A5077200969 @default.
• W3165157607 creator A5081983005 @default.
• W3165157607 creator A5084588976 @default.
• W3165157607 creator A5087302585 @default.
• W3165157607 creator A5088495720 @default.
• W3165157607 creator A5089482025 @default.
• W3165157607 date "2021-05-27" @default.
• W3165157607 modified "2023-10-12" @default.
• W3165157607 title "Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study" @default.
• W3165157607 cites W1498301041 @default.
• W3165157607 cites W1702796904 @default.
• W3165157607 cites W1962029512 @default.
• W3165157607 cites W1967642097 @default.
• W3165157607 cites W1985945455 @default.
• W3165157607 cites W1988017103 @default.
• W3165157607 cites W1991971927 @default.
• W3165157607 cites W2009792683 @default.
• W3165157607 cites W2019120380 @default.
• W3165157607 cites W2022279737 @default.
• W3165157607 cites W2039937642 @default.
• W3165157607 cites W2047379349 @default.
• W3165157607 cites W2053916731 @default.
• W3165157607 cites W2069585474 @default.
• W3165157607 cites W2082944347 @default.
• W3165157607 cites W2087577664 @default.
• W3165157607 cites W2105688337 @default.
• W3165157607 cites W2106515170 @default.
• W3165157607 cites W2115861424 @default.
• W3165157607 cites W2119852447 @default.
• W3165157607 cites W2124681501 @default.
• W3165157607 cites W2135527227 @default.
• W3165157607 cites W2136040391 @default.
• W3165157607 cites W2151611462 @default.
• W3165157607 cites W2151779725 @default.
• W3165157607 cites W2154556265 @default.
• W3165157607 cites W2155513557 @default.
• W3165157607 cites W2160141785 @default.
• W3165157607 cites W2168235467 @default.
• W3165157607 cites W2186765448 @default.
• W3165157607 cites W2217874059 @default.
• W3165157607 cites W2392339987 @default.
• W3165157607 cites W2554018612 @default.
• W3165157607 cites W2600568507 @default.
• W3165157607 cites W2602444563 @default.
• W3165157607 cites W2612300503 @default.
• W3165157607 cites W2612655633 @default.
• W3165157607 cites W2731616294 @default.
• W3165157607 cites W2763250779 @default.
• W3165157607 cites W2767947916 @default.
• W3165157607 cites W2784429314 @default.
• W3165157607 cites W2790545717 @default.
• W3165157607 cites W2794227656 @default.
• W3165157607 cites W2803173125 @default.
• W3165157607 cites W2809330972 @default.
• W3165157607 cites W2887026479 @default.
• W3165157607 cites W2921655682 @default.
• W3165157607 cites W2936365596 @default.
• W3165157607 cites W2942678593 @default.
• W3165157607 cites W2945829189 @default.
• W3165157607 cites W2948505468 @default.
• W3165157607 cites W2949260349 @default.
• W3165157607 cites W2981232846 @default.
• W3165157607 cites W3005615743 @default.
• W3165157607 cites W3018409450 @default.
• W3165157607 cites W3099584915 @default.
• W3165157607 cites W3131191777 @default.
• W3165157607 doi "https://doi.org/10.1371/journal.pmed.1003615" @default.
• W3165157607 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8158920" @default.
• W3165157607 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34043628" @default.
• W3165157607 hasPublicationYear "2021" @default.
• W3165157607 type Work @default.
• W3165157607 sameAs 3165157607 @default.
• W3165157607 citedByCount "27" @default.
• W3165157607 countsByYear W31651576072021 @default.
• W3165157607 countsByYear W31651576072022 @default.
• W3165157607 countsByYear W31651576072023 @default.

• next